Tirzepatide: what it is, what it does, and whether it might be right for you

Two receptors, one medicine: why that distinction matters

Most injectable weight-loss medicines work on a single gut hormone called GLP-1. Tirzepatide goes further by also activating GIP (glucose-dependent insulinotropic polypeptide). Both hormones are released after eating and play a role in telling the brain you are full, slowing gastric emptying, and supporting blood-sugar control. Hitting both pathways together appears to produce a larger effect on appetite than either signal alone.

That is the mechanism in plain terms. What it means practically is that many people find their appetite drops noticeably after the first few weeks, portions that once felt normal begin to feel like too much, and the pull towards high-calorie foods weakens. The medicine does not do the eating for you, but it shifts the biology enough that the effort of eating less feels considerably lighter. The NHS tirzepatide page describes this mechanism and the common side effects clearly if you want the patient-facing summary.

It is worth being precise about what tirzepatide does not do: it is not a stimulant, not a fat-blocker, and not a replacement for food. Lifestyle changes (eating patterns and physical activity) remain part of the licensed treatment framework. The medicine creates the conditions for those changes to stick.

Who tirzepatide is actually licensed to treat

The UK licence covers two groups. First, adults managing their weight: a BMI of 30 or above, or a BMI from 27 upward if at least one weight-related condition is present (conditions such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, or prediabetes). Second, adults with type 2 diabetes needing better blood-sugar control alongside other treatments.

NICE's appraisal (TA1026, published December 2024) sets a narrower bar for NHS prescribing: a BMI of 35 or above plus at least one qualifying comorbidity, with lower thresholds applying for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. If you fall below the NHS threshold, or simply do not want to wait, a private route through a regulated pharmacy is a lawful alternative, provided a prescriber assesses you first. Understanding the eligibility picture is a good starting point; you can read more on who tirzepatide is suitable for.

BMI alone never determines approval. A prescriber looks at the whole clinical picture: your medical history, any medicines you already take, conditions that would make tirzepatide unsuitable (including a history of medullary thyroid carcinoma or pancreatitis), and whether you are pregnant, trying to conceive, or breastfeeding, none of which are compatible with tirzepatide treatment.

The side-effect profile: what most people actually experience

The most commonly reported effects are gastrointestinal. Nausea, loose stools, constipation, reflux and a general feeling of fullness that tips into discomfort are all well-documented. For most people, these are most noticeable in the first few days after a new dose level, and they tend to settle as the body adjusts. The slow titration schedule (beginning at 2.5 mg, a dose whose job is to let your system adapt rather than to drive weight loss) exists precisely to keep this manageable.

Less common but more serious effects include symptoms of pancreatitis: severe stomach pain that radiates to the back, with or without vomiting. The MHRA issued a specific Drug Safety Update on this in January 2026. If that happens, stop the injection and get medical help promptly rather than waiting for the next dose day. Gallbladder problems, allergic reactions, and signs of dehydration from persistent vomiting or diarrhoea are also reasons to seek medical advice without delay.

One practical habit worth building: before each weekly injection, check that the liquid in the pen window is clear and colourless, and if you are curious about what tirzepatide actually contains, understanding the formulation can help you know what you are looking at. The full ingredient and formulation detail explains what you are looking at.

Tirzepatide, Mounjaro, and the prescription question

In the UK, tirzepatide is sold under the brand name Mounjaro. They are the same medicine; the generic name is tirzepatide, the commercial name is Mounjaro. If you have seen references to Zepbound, that is the US brand name and it is not available here.

Because tirzepatide is a prescription-only medicine, the only lawful route to it is through a clinical assessment by a registered prescriber. That assessment exists for good reason: the same properties that make it effective (slower gastric emptying, altered gut-hormone signalling) can cause harm in certain medical contexts, and the dosing decisions across six strength levels genuinely require clinical oversight. You can read about the relationship between tirzepatide and Mounjaro in more detail, or explore what private treatment typically costs in the UK if that is where your thinking is.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day it is submitted. No algorithms make clinical decisions here. If you are weighing up whether tirzepatide is worth exploring, a good next step is to look at the treatment options we offer or to start your free consultation and let a prescriber review your situation properly.